New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications
Type 1 diabetes (T1D) is not only a disorder of insulin production from beta cell destruction, but also a progressive condition that brings about life-threatening complications such as diabetic nephropathy, impaired wound recovery, and cardiovascular disease. Mesenchymal stromal cell (MSC) use has r...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Clinical Diabetes and Healthcare |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcdhc.2025.1586061/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850273187880763392 |
|---|---|
| author | Deeptha Bejugam Sarah Bu Athena N. Nguyen Mariam Yaltaghian Kinga K Smolen Kinga K Smolen |
| author_facet | Deeptha Bejugam Sarah Bu Athena N. Nguyen Mariam Yaltaghian Kinga K Smolen Kinga K Smolen |
| author_sort | Deeptha Bejugam |
| collection | DOAJ |
| description | Type 1 diabetes (T1D) is not only a disorder of insulin production from beta cell destruction, but also a progressive condition that brings about life-threatening complications such as diabetic nephropathy, impaired wound recovery, and cardiovascular disease. Mesenchymal stromal cell (MSC) use has recently become an encouraging new way to treat these complications and can result in better health outcomes for T1D patients. Some research has shown that MSC injections into mice and rat models have resulted in reduced mesangial cell thickening, inflammatory mediator recruitment, proteinuria, and fibrosis normally seen in diabetic nephropathy. Other studies have demonstrated that MSCs aid wound healing by increasing anti-inflammatory M2 macrophage differentiation, stimulating angiogenesis and collagen synthesis, and signaling the proliferation and migration of dermal fibroblasts toward injury sites. Additionally, there is evidence that MSCs are capable of activating the PI3K pathway and exhibiting antioxidant effects in murine models experiencing diabetic-related heart disease. However, given these efforts, further research is needed to establish the prolonged safety and efficacy of MSC use in humans to treat T1D. |
| format | Article |
| id | doaj-art-4f4bb866a6f64475934a2b3e1596b7d5 |
| institution | OA Journals |
| issn | 2673-6616 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Clinical Diabetes and Healthcare |
| spelling | doaj-art-4f4bb866a6f64475934a2b3e1596b7d52025-08-20T01:51:35ZengFrontiers Media S.A.Frontiers in Clinical Diabetes and Healthcare2673-66162025-05-01610.3389/fcdhc.2025.15860611586061New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complicationsDeeptha Bejugam0Sarah Bu1Athena N. Nguyen2Mariam Yaltaghian3Kinga K Smolen4Kinga K Smolen5Georgetown University School of Medicine, Washington, DC, United StatesGeorgetown University School of Medicine, Washington, DC, United StatesGeorgetown University School of Medicine, Washington, DC, United StatesGeorgetown University School of Medicine, Washington, DC, United StatesPrecision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United StatesHarvard Medical School, Boston, MA, United StatesType 1 diabetes (T1D) is not only a disorder of insulin production from beta cell destruction, but also a progressive condition that brings about life-threatening complications such as diabetic nephropathy, impaired wound recovery, and cardiovascular disease. Mesenchymal stromal cell (MSC) use has recently become an encouraging new way to treat these complications and can result in better health outcomes for T1D patients. Some research has shown that MSC injections into mice and rat models have resulted in reduced mesangial cell thickening, inflammatory mediator recruitment, proteinuria, and fibrosis normally seen in diabetic nephropathy. Other studies have demonstrated that MSCs aid wound healing by increasing anti-inflammatory M2 macrophage differentiation, stimulating angiogenesis and collagen synthesis, and signaling the proliferation and migration of dermal fibroblasts toward injury sites. Additionally, there is evidence that MSCs are capable of activating the PI3K pathway and exhibiting antioxidant effects in murine models experiencing diabetic-related heart disease. However, given these efforts, further research is needed to establish the prolonged safety and efficacy of MSC use in humans to treat T1D.https://www.frontiersin.org/articles/10.3389/fcdhc.2025.1586061/fulltype I diabetesstem cellsdiabetic nephropathydiabetic wound healingdiabetic cardiovascular diseasemesenchymal stromal cells |
| spellingShingle | Deeptha Bejugam Sarah Bu Athena N. Nguyen Mariam Yaltaghian Kinga K Smolen Kinga K Smolen New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications Frontiers in Clinical Diabetes and Healthcare type I diabetes stem cells diabetic nephropathy diabetic wound healing diabetic cardiovascular disease mesenchymal stromal cells |
| title | New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications |
| title_full | New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications |
| title_fullStr | New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications |
| title_full_unstemmed | New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications |
| title_short | New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications |
| title_sort | new frontiers in type i diabetes treatment the impact of mesenchymal stromal cells on long term complications |
| topic | type I diabetes stem cells diabetic nephropathy diabetic wound healing diabetic cardiovascular disease mesenchymal stromal cells |
| url | https://www.frontiersin.org/articles/10.3389/fcdhc.2025.1586061/full |
| work_keys_str_mv | AT deepthabejugam newfrontiersintypeidiabetestreatmenttheimpactofmesenchymalstromalcellsonlongtermcomplications AT sarahbu newfrontiersintypeidiabetestreatmenttheimpactofmesenchymalstromalcellsonlongtermcomplications AT athenannguyen newfrontiersintypeidiabetestreatmenttheimpactofmesenchymalstromalcellsonlongtermcomplications AT mariamyaltaghian newfrontiersintypeidiabetestreatmenttheimpactofmesenchymalstromalcellsonlongtermcomplications AT kingaksmolen newfrontiersintypeidiabetestreatmenttheimpactofmesenchymalstromalcellsonlongtermcomplications AT kingaksmolen newfrontiersintypeidiabetestreatmenttheimpactofmesenchymalstromalcellsonlongtermcomplications |